



Artificial Intelligence in Deep Brain Stimulation

Guest Editors:

Dr. Joshua Wong

Norman Fixel Institute for
Neurological Diseases, University
of Florida, Gainesville, FL 32608,
USA

Dr. Jun Yu

Norman Fixel Institute for
Neurological Diseases, University
of Florida, Gainesville, FL 32608,
USA

Deadline for manuscript
submissions:

closed (15 June 2023)

Message from the Guest Editors

The use of deep brain stimulation (DBS) for a variety of neurological and psychiatric disorders is one of the most important advances in clinical neuroscience over the past two decades. DBS enables neuroscientists to obtain direct measures of neuronal activities, interrogate the function of neural circuits, and investigate the therapeutic potential of modulating these circuits with unprecedented spatial and temporal precision.

This Special Issue of *Biomedicines*, “Artificial Intelligence in Deep Brain Stimulation”, will mainly focus on the recent advances in the application of AI in DBS to contextualize the current body of research and discuss potential future directions. We cordially invite authors to submit original research or review articles pertaining to this important and fast-growing field. The goal is to stimulate research and clinical interests in this exciting field of biomedicine with the hope of developing strategies to integrate artificial intelligence for precision neuromodulation therapy.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)